Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
April 20, 2017Journal of Clinical Oncology

Lenalidomide Maintenance Compared With Placebo in Responding Elderly Patients With Diffuse Large B-Cell Lymphoma Treated With First-Line Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone

View Full Paper
Ask AI
Bookmark
Share

Authors

CTCatherine ThiéblemontHTHervé TillyMSMaría Gomes da Silva

Discussion

Loading...

Member takes

Overview

Key Points

Key points are not available for this paper at this time.

Cite This Study

Thiéblemont et al. (2017) studied this question.

synapsesocial.com/papers/6a77ca65de5e3adfbdf73bdahttps://doi.org/10.1200/jco.2017.72.6984
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 4 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Rituximab maintenance improves survival in male patients with diffuse large B-cell lymphoma. Results of the HD2002 prospective multicentre randomized phase III trial2015 · 36 citations
  2. 2Chronic lymphocytic leukemia T cells show impaired immunological synapse formation that can be reversed with an immunomodulating drug2008 · 601 citations
  3. 3Lenalidomide Combined With R-CHOP Overcomes Negative Prognostic Impact of Non–Germinal Center B-Cell Phenotype in Newly Diagnosed Diffuse Large B-Cell Lymphoma: A Phase II Study2014 · 364 citations
  4. 4A Predictive Model for Aggressive Non-Hodgkin's Lymphoma1993 · 5,009 citations